BioTuesdays
AIM ImmunoTech Logo
Markets

Maxim ups AIM ImmunoTech PT to $5 from $2

Maxim Group raised its price target for AIM ImmunoTech (NYSE American:AIM) to $5 from $2, citing a strengthened balance sheet and a $14.54-million award from the NCI to study its Ampligen drug candidate in up to five...

April 6, 2020
IDEAYA Biosciences Logo
Markets

HCW starts IDEAYA Biosciences at buy; PT $13

H.C. Wainwright launched coverage of IDEAYA Biosciences (NASDAQ:IDYA) with a “buy” rating and $13 price target. The stock closed at $3.59 on April 3. Analyst Edward White writes that IDE196 is the company’s potent...

April 6, 2020
Imara
Markets

SVB Leerink starts Imara at OP; PT $25

SVB Leerink initiated coverage of Imara (NASDAQ:IMRA) with an “outperform” rating and $25 price target in 12 months. The stock closed at $15.75 on April 3. Imara is focused on developing and commercializing novel...

April 6, 2020
Molecular Partners
Markets

HCW starts Molecular Partners at buy; PT CHF29

H.C. Wainwright initiated coverage of Swiss-based Molecular Partners (SWX:MOLN) with a “buy” rating and price target of CHF29. The stock closed at CHF17.54 on April 1. Molecular Partners is developing targeted therapies...

April 2, 2020
Chembio Diagnostics
Markets

Canaccord ups Chembio Diagnostics PT to $10 from $7

Canaccord Genuity raised its price target for Chembio Diagnostics (NASDAQ:CEMI) to $10 from $7, citing the launch of its 15-minute dual path platform (DPP) COVID-19 serology test in the U.S. The stock closed at $7.16 on...

April 2, 2020
Profound Medical Logo
Markets

Cowen starts Profound Medical at OP; PT $15 (U.S.)

Cowen launched coverage of Profound Medical (NASDAQ:PROF; TSX:PRN) with an “outperform” rating and $15 (U.S.) price target. The stock closed at $9.74 on March 31. “[Profound’s] TULSA-PRO is a proprietary platform that...

April 1, 2020
AVEO Pharmaceuticals Logo
Markets

HCW cuts AVEO Pharma PT to $4 from $6

H.C. Wainwright lowered its price target for AVEO Pharmaceuticals (NASDAQ:AVEO) to $4 from $6, but reiterated a “buy” rating, citing discontinuation of the company’s ficlatuzumab program because of COVID-19 and reduced...

April 1, 2020
Aileron Therapeutics Logo
Markets

HCW halves Aileron Therapeutics PT to $3

H.C. Wainwright lowered its price target for Aileron Therapeutics (NASDAQ:ALRN) to $3 from $6, citing the removal of lead drug candidate, ALRN-6924, in combination with Ibrance in murine double minute 2 (MDM2) gene...

March 31, 2020
BeyondSpring Logo
Markets

HCW cuts BeyondSpring PT to $30 from $41

H.C. Wainwright lowered its price target for BeyondSpring (NASDAQ:BTSI) to $30 from $41, but reiterated a “buy” rating, citing a higher discount rate to account from increased uncertainty of COVID-19’s impact on...

March 30, 2020
Edesa Biotech
Markets

Brookline starts Edesa Biotech at buy; PT $10

Brookline Capital Markets launched coverage of Edesa Biotech (NASDAQ:EDSA) with a “buy” rating and $10 price target. The stock closed at $2.16 on March 27. Edesa is developing EB01, a topical sPLA2 inhibitor that...

March 30, 2020
AB Science Logo
Markets

HCW starts AB Science at buy; PT €9.00

H.C. Wainwright initiated coverage of AB Science (Euronext – FR0010557264 – AB) with a “buy” rating and price target of €9.00. The stock closed at €6.78 on March 27. AB Science’s lead product, masitinib, is...

March 30, 2020
PDS Biotechnology Logo
Markets

HCW cuts PDS Biotechnology to neutral; removes PT

H.C. Wainwright downgraded PDS Biotechnology (NASDAQ:PDSB) to “neutral” from “buy” and removed its price target, citing recent significant dilution and lack of meaningful catalysts over the remainder of the year “prompt...

March 30, 2020
soliton-logo
Markets

Roth starts Soliton at buy; PT $14

Roth Capital Partners launched coverage of Soliton (NASDAQ:SOLY) with a “buy” rating and $14 price target. The stock closed at $8.80 on March 26. Soliton is an aesthetic company that utilizes acoustic pulse technology...

March 27, 2020
Cipher Pharmaceuticals
Markets

Mackie cuts Cipher Pharma PT to $1 from $2.30

Mackie Research lowered its price target for Cipher Pharmaceuticals (TSX:CPH) to $1 (Canadian) from $2.30, citing a delay in the out-licensing of its Canadian assets because of a dispute with Bausch Health (NYSE:BHC)...

March 27, 2020
atyr Pharma
Markets

HCW cuts aTyr Pharma to neutral and removes PT

H.C. Wainwright downgraded aTyr Pharma (NASDAQ:LIFE) to “neutral” from “buy” and removed its price target, citing delays in topline results from a Phase 1b/2a trial of ATYR1923 for the treatment of sarcoidosis, an...

March 27, 2020
Eyenovia Logo
Markets

Ladenburg cuts Eyenovia PT to $19 from $30

Ladenburg Thalmann lowered its price target for Eyenovia (NASDAQ:EYEN) to $19 from $30, but reiterated its “buy” rating, reflecting dilution associated with a recent financing and anticipated additional dilution...

March 26, 2020
T2 Biosystems Logo
Markets

AGP cuts T2 Biosystems PT to $1.10 from $1.80

Alliance Global Partners lowered its price target for T2 Biosystems (NASDAQ:TTOO) to $1.10 from $1.80 after the company released lower than expected first quarter results but added a COVID-19 program to its platform...

March 26, 2020
OpGen Logo
Markets

AGP ups OpGen PT to $5 from $2.50

Alliance Global Partners raised its price target for OpGen (NASDAQ:OPGN) to $5 from $2.50 after the company reported better than expected fourth quarter results. The stock closed at $2.99 on March 24. OpGen also...

March 25, 2020